10 reports

  • REST OF THE WORLD RNAI TECHNOLOGY MARKET, 2014-2022 (IN USD MILLION)
  • GLOBAL RNAI TECHNOLOGY MARKET, 2014-2022 (IN USD MILLION)
  • RNAi
  • Alnylam Pharmaceuticals, Inc.
  • Arcturus Therapeutics, Inc.
  • QIAGEN N.V.
  • Sirna Therapeutics, Inc.

##. ## US RNAi Therapies Market 2015-2025 ##. ##. ## FDA Approval of Kynamro Improves RNAi Prospects ##. ## EU## RNAi Therapies Market 2015-2025 ##. ##. ## RNAi Prospects in Leading EU Markets ##. ## Asia-Pacific RNAi Therapies Market 2015-2025 ##. ##. ## Prospects for

  • Biological Therapy
  • RNAi
  • Therapy
  • World

Introduction to RNA Interference (RNAi) Therapy ##. ## Need for RNAi Therapy ##. ## RNAi Technologies ##.

  • Biological Therapy
  • RNAi
  • World

Agrow: RNAi

2709 2980 2303

Agrow: RNAi Contents ## Executive Summary ## Chapter ##: Introduction ## Chapter ##: RNAi for controlling insects and other pests ## Chapter ##: RNAi in other crop sectors ## Chapter ##: Formulation and delivery of RNAi technology ## Chapter ##: Crop protection companie

  • Biological Therapy
  • RNAi
  • RNAi Technology
  • United States
  • Litigation And Patent
  • Dicerna Pharma Enters Into Licensing Agreement With Plant Bioscience For Baulcombe & Hamilton RNAi Patents
  • 02/25/2016: DICERNA REPORTS PROGRESS WITH GALNAC-DSIRNA-EX-CONJUGATES
  • Pharmaceutical
  • RNAi
  • United States
  • Company
  • Dicerna Pharmaceuticals, Inc.
  • FEB 07, 2017: RXI PHARMACEUTICALS APPOINTS LEADING ONCOLOGY EXPERT, DR. ROLF KIESSLING, TO SCIENTIFIC ADVISORY BOARD
  • AUG 08, 2017: RXI PHARMACEUTICALS SELECTS RXI-804 FOR PRECLINICAL DEVELOPMENT
  • RNAi
  • United States
  • Company
  • Company Operations
  • RXi Pharmaceuticals Corporation
  • Alnylam Pharmaceuticals, Inc. - Dormant Developmental Projects,2016
  • ALN-HBV
  • RNAi
  • Therapy
  • United States
  • Product Initiative
  • Alnylam Pharmaceuticals, Inc.

RNAi product candidates into human clinical testing.

  • RNAi
  • United States
  • Company
  • Corporate Finance
  • Arbutus Biopharma Corporation

Tekmira has entered into a product development agreement with Roche to advance Roche' s first two RNA interference (RNAi) product candidates into human clinical testing.

  • RNAi
  • United States
  • Company
  • Corporate Finance
  • Tekmira Pharmaceuticals Corporation
  • RXI PHARMACEUTICALS CORPORATION - DORMANT DEVELOPMENTAL PROJECTS,2016
  • RXI PHARMACEUTICALS CORPORATION - PRECLINICAL, 2016
  • Pharmaceutical
  • RNAi
  • United States
  • Product Initiative
  • RXi Pharmaceuticals Corporation